Journal: Frontiers in Immunology
Article Title: A novel mRNA-based therapeutic vaccine elicits robust anti-tumor immunity against HPV-associated malignancies
doi: 10.3389/fimmu.2026.1823374
Figure Lengend Snippet: TriStim-E6/E7 mRNA induced T cell activation and proliferation in vitro . (A, B) HEK293 cells co-transfected with 0.25 μg of mb-α-CD3 mRNA and 5 μg of TriStim-E6/E7 mRNA, were used to stimulate mouse splenocytes. The expression of CD69 (A) and CD25 (B) in splenic T cells was assessed by flow cytometry analysis. Control groups included HEK293 cells transfected with empty LNPs, 0.25 μg of mb-α-CD3 mRNA alone, or combination of 0.25 μg of mb-α-CD3 mRNA and 5 μg of E6/E7-P2P16-MITD mRNA. (C, D) HEK293 cells co-transfected with 0.25 μg of mb-α-CD3 mRNA and 5 μg of TriStim-E6/E7 mRNA, were treated with mitomycin C before co-cultured with mouse splenocytes. The proliferation of CFSE-prestained mouse splenic T cells were assessed by flow cytometry. Control groups included HEK293 cells transfected with empty LNPs, 0.25 μg of mb-α-CD3 mRNA alone, or combination of 0.25 μg of mb-α-CD3 mRNA and 5 μg of E6/E7-P2P16-MITD mRNA. Data are presented as the mean ± standard deviation (n = 3). Statistical analysis was conducted using an unpaired, two-tailed Student’s t-test; **P ≤ 0.01, ***P ≤ 0.001.
Article Snippet: To assess T cell proliferation, mRNA-transfected HEK293 cells were treated with 15 μg/mL mitomycin C (Cat. #HY-13316, MedChemExpress, Shanghai, China) for 4 hours to inhibit cell growth.
Techniques: Activation Assay, In Vitro, Transfection, Expressing, Flow Cytometry, Control, Cell Culture, Standard Deviation, Two Tailed Test